LGR5 in breast cancer and ductal carcinoma in situ: a diagnostic and prognostic biomarker and a therapeutic target

Table 1 Correlation between LGR5 expression and clinicopathologic features in primary breast cancer

Variable	Patients N (%)	LGR5 intensity				R	P value
		0	1	2	3
All	401 (100)	69	157	151	24
Age
< 50	67 (16.7)	8	32	23	4	- 0.003	0.95
≥ 50	334 (83.3(	61	125	128	20
Tumor size
≤ 20 mm	232 (57.9)	32	82	104	14	−0.162	0.001
> 20 mm	169 (42.1)	37	75	47	10
Ki67
0–10%	139 (36.4)	27	48	57	7	0.012	0.81
11–25%	127 (33.2)	23	45	43	9
> 25%	116 (30.4)	17	48	43	8
NHG
1	93 (23.3)	13	31	44	5	−0.100	0.047
2	161 (40.3)	30	58	63	10
3	146 (36.5)	26	67	44	9
Nodal metastasis
No	208 (57.8)	24	86	87	11	−0.162	0.002
Yes	152 (42.2)	38	60	49	5
ER
≤ 10%	61 (15.2)	3	23	26	9	−0.166	0.001
> 10%	340 (84.4)	66	134	125	15
PR
≤ 10%	125 (31.2)	20	45	48	12	−0.70	0.16
> 10%	276 (68.8)	49	112	103	12
Luminal A	214 (53.6)	41	87	77	9	−0.092	0.065
Luminal B	35 (8.8)	8	13	13	1	−0.043	0.40
HER2	22 (5.5)	0	9	10	3	0.110	0.028
Basal	136 (34.3)	15	55	55	11	0.103	0.040

Abbreviations: LGR5 Leucine-rich repeat-containing G-protein coupled receptor 5, R correlation coefficient, NHG Nottingham histologic score, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor. Spearman correlation, two-tailed- value. Bold indicates P -value < 0.05

ISSN: 1471-2407